ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
ARIAD Pharma (ARIA) Announces Completion of European Ops Sale to Incyte (INCY)
June 2, 2016 7:36 AM EDTARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced license agreement for Incyte to exclusively license Iclusig... More
Incyte (INCY) Europe Granted Exclusive Iclusig Development, Commercialization Rights in EU, Additional Countries (ARIA)
June 1, 2016 4:13 PM EDTIncyte (NASDAQ: INCY) disclosed the following on Wednesday:
Item 1.01 Entry Into a Material Definitive Agreement.
On June 1, 2016, an Amended and Restated Buy-in License Agreement was entered into by ARIAD Pharmaceuticals, Inc. (ARIAD), ARIAD Pharmaceuticals (Europe) S.a.r.l. (ARIAD Europe), and Incyte Corporation (Incyte), as guarantor (the License Agreement). ARIAD Europe is one of the entities that became owned by Incyte Europe S.Ã .r.l. (Incyte Europe), a wholly-owned subsidiary of Incyte, upon the closing of the Acquisition described under Item 2.01 below. ARIAD Europe and Incyte Europe are collectively referred to in the remainder of... More
